Presbia PLC is covered by the following analysts.
02-23-2015 I Can See Clearly Now; Initiating LENS with Buy Rating, $12 Target
09-08-2015 Revisiting LENS as Clinical and Commercial Plans Come into Focus
11-17-2015 Commercial and Clinical Plans Progressing
12-17-2015 LENS Sharpens Plans as Commercialization Unfolds
04-25-2016 Clinical Progress Continues
05-17-2016 Call with Dr. Kerry Assil on Presbia's Microlens; Takeaways and Transcript
Rodman & Renshaw
Raghuram Selvaraju, Ph.D.
05-22-2017 Pre-Market Approval Application Completion Approaching; Reducing PT to $12
05-23-2016 Additional Interim Data Reported; Financial Projections Revised; Reiterate Buy
05-10-2016 Making Presbyopia Part of the Past; Initiating at Buy with $14.00 Target
Please note that any opinions, estimates or forecasts regarding Presbia PLC's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Presbia PLC or its management. Presbia PLC does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.